Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial

Peter Bergman, Ola Blennow, Lotta Hansson, Stephan Mielke, Piotr Nowak, Puran Chen, Gunnar Söderdahl, Anders Österborg, C. I. Edvard Smith, David Wullimann, Jan Vesterbacka, Gustaf Lindgren, Lisa Blixt, Gustav Friman, Emilie Wahren-Borgström, Anna Nordlander, Angelica Cuapio Gomez, Mira Akber, Davide Valentini, Anna-Carin Norlin, Anders Thalme, Gordana Bogdanovic, Sandra Muschiol, Peter Nilsson, Sophia Hober, Karin Loré, Margaret Sällberg Chen, Marcus Buggert, Hans-Gustaf Ljunggren, Per Ljungman, Soo Aleman, the COVAXID-collaborator group (shown separately)
doi: https://doi.org/10.1101/2021.09.07.21263206
Back to top
Posted September 14, 2021.
Download PDF

Supplementary Material

Data/Code
Email
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial
Peter Bergman, Ola Blennow, Lotta Hansson, Stephan Mielke, Piotr Nowak, Puran Chen, Gunnar Söderdahl, Anders Österborg, C. I. Edvard Smith, David Wullimann, Jan Vesterbacka, Gustaf Lindgren, Lisa Blixt, Gustav Friman, Emilie Wahren-Borgström, Anna Nordlander, Angelica Cuapio Gomez, Mira Akber, Davide Valentini, Anna-Carin Norlin, Anders Thalme, Gordana Bogdanovic, Sandra Muschiol, Peter Nilsson, Sophia Hober, Karin Loré, Margaret Sällberg Chen, Marcus Buggert, Hans-Gustaf Ljunggren, Per Ljungman, Soo Aleman, the COVAXID-collaborator group (shown separately)
medRxiv 2021.09.07.21263206; doi: https://doi.org/10.1101/2021.09.07.21263206
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area